Dr_Microbe/iStock.
Called Upstaza, the therapy not only improved the symptoms of all participants in the small-scale trial but also gave some children the ability to walk and talk for the first time.
Category: genetics – Page 218
(http://www.pharma.unizg.hr/en/about-us/staff/gordan–lauc, 450.html) is Professor of Biochemistry and Molecular Biology at the University of Zagreb, Faculty of Pharmacy and Biochemistry, and Founder and CEO of Genos Ltd. (https://genos-glyco.com/), a research-intensive SME located in Zagreb, Croatia with core of expertise in molecular genetics and glycomics (The comprehensive study the entire complement of sugars, whether free or present in more complex molecules of an organism) and they perform contract research, contract analysis and service for numerous universities, hospitals and private individuals in Europe and overseas.
Prof. Dr. Lauc also is CSO of GlycanAge LTD (https://glycanage.com/), a company that has developed a ground-breaking test that analyses your personal glycobiome for insights in improving your health and monitoring your biological age, and Co-Director of the Human Glycome Project (https://human-glycome.org/).
Prof. Dr. Lauc graduated with a degree in molecular biology at the University of Zagreb Faculty of Science in 1992, and obtained Ph.D. in Biochemistry and the University of Zagreb in 1995. He got his postdoctoral training at the Institute for Medical Physics and Biophysics in Münster and Johns Hopkins University in Baltimore. Since 1993 he has been employed at the Faculty of Pharmacy and Biochemistry in Zagreb. Between 1998 and 2010 he was also part-time employed at the University of Osijek School of Medicine where he founded a DNA laboratory for the identification of war victims and also served as Vice-Dean for Science between 2001 and 2005.
Prof. Dr. Lauc is author of over 100 research papers published in international journals and six international patents. He was invited to lecture at numerous international conferences, elected for visiting professor at the Johns Hopkins University and in 2011 also inducted in the prestigious Johns Hopkins Society of Scholars. If 2012 he was appointed Honorary Professor at the University of Edinburgh and Adjunct Professor at the Edith Cowan University in Perth.
Prof. Dr. Lauc chaired a number of conferences, including the “European Science Foundation Exploratory Workshop on Glycoscience” which resulted in the creation of the “European Glycoscience Forum”.
Prof. Dr. Lauc was a chairman of the committee that prepared Croatian National Action plan for the increased investment in research in development (2007), and was a member of the National Science Council between 2009 and 2013 and also and President of the National Council for Natural Sciences. He is a President-elect of the International Glycoscience Organization and member of the Steering Committee of the European Glycoscience Forum.
Occupation-related stress and work characteristics are possible determinants of social inequalities in epigenetic aging but have been little investigated. Here, we investigate the association of several work characteristics with epigenetic age acceleration (AA) biomarkers.
The study population included employed and unemployed men and women (n = 631) from the UK Understanding Society study. We evaluated the association of employment and work characteristics related to job type, job stability; job schedule; autonomy and influence at work; occupational physical activity; and feelings regarding the job with four epigenetic age acceleration biomarkers (Hannum, Horvath, PhenoAge, GrimAge) and pace of aging (DunedinPoAm, DunedinPACE).
We fitted linear regression models, unadjusted and adjusted for established risk factors, and found the following associations for unemployment (years of acceleration): HorvathAA (1.51, 95% CI 0.08, 2.95), GrimAgeAA (1.53, 95% CI 0.16, 2.90) and 3.21 years for PhenoAA (95% CI 0.89, 5.33). Job insecurity increased PhenoAA (1.83, 95% CI 0.003, 3.67), while working at night was associated with an increase of 2.12 years in GrimAgeAA (95% CI 0.69, 3.55). We found effects of unemployment to be stronger in men and effects of night shift work to be stronger in women.
BECOMING a parent for the first time is a major moment for anyone — but for Laura Gayton, giving birth to a healthy, crying baby boy…
The recently identified, globally predominant SARS-CoV-2 Omicron variant (BA.1) is highly transmissible, even in fully vaccinated individuals, and causes attenuated disease compared with other major viral variants recognized to date1 – 7. The Omicron spike (S) protein, with an unusually large number of mutations, is considered the major driver of these phenotypes3,8. We generated chimeric recombinant SARS-CoV-2 encoding the S gene of Omicron in the backbone of an ancestral SARS-CoV-2 isolate and compared this virus with the naturally circulating Omicron variant. The Omicron S-bearing virus robustly escapes vaccine-induced humoral immunity, mainly due to mutations in the receptor-binding motif (RBM), yet unlike naturally occurring Omicron, efficiently replicates in cell lines and primary-like distal lung cells. In K18-hACE2 mice, while Omicron causes mild, non-fatal infection, the Omicron S-carrying virus inflicts severe disease with a mortality rate of 80%. This indicates that while the vaccine escape of Omicron is defined by mutations in S, major determinants of viral pathogenicity reside outside of S.
The authors have declared no competing interest.
Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible treatment for atrial fibrillation.
The study, published in Cell Reports Medicine, built on ongoing collaborative Cleveland Clinic research to support further investigation into metformin as a drug repurposing candidate. Researchers used advanced computation and genetic sequencing to determine that metformin’s targets overlap significantly with genes dysregulated in atrial fibrillation.
Finding drugs or procedures to treat atrial fibrillation is difficult because of potential serious side effects. There is a significant need for new treatments for atrial fibrillation as there have been no new drugs approved in more than a decade.
Genomic medicine is undergoing rapid change after the Japanese public health insurance system began to cover genetic testing in 2019. Cancer patients who meet certain criteria are able to take these tests for a relatively affordable price, and their genetic information is collected in a massive database and analyzed with the help of around 170 hospitals across the country. But challenges remain, with suitable drugs available for only 10% of patients who undergo testing.
Quantum effects play a hitherto unexpected role in creating instabilities in DNA – the so-called “molecule of life” that provides instructions for cellular processes in all living organisms. This conclusion, based on work by researchers at the University of Surrey in the UK, goes against long-held beliefs that quantum behaviour is not relevant in the wet, warm environment of cells, and could have far-reaching consequences for models of genetic mutation.
The two strands of the DNA double helix are linked together by hydrogen bonds between the DNA bases. There are typically four different bases, called Guanine (G), Cytosine ©, Adenine (A) and Thymine (T). In the standard configuration, A always bonds to T while C always bonds to G. However, if the protons (nuclei of the hydrogen atoms) that make up the bonds hop from one strand of DNA to the other then a genetic mutation can occur.
\r \r
*Intelligence Beyond the Brain: morphogenesis as an example of the scaling of basal cognition*
*Description:*
Each of us takes the remarkable journey from physics to mind: we start life as a quiescent oocyte (collection of chemical reactions) and slowly change and acquire an advanced, centralized mind. How does unified complex cognition emerge from the collective intelligence of cells? In this talk, I will use morphogenesis to illustrate how evolution scales cognition across problem spaces. Embryos and regenerating organs produce very complex, robust anatomical structures and stop growth and remodeling when those structures are complete. One of the most remarkable things about morphogenesis is that it is not simply a feed-forward emergent process, but one that has massive plasticity: even when disrupted by manipulations such as damage or changing the sizes of cells, the system often manages to achieve its morphogenetic goal. How do cell collectives know what to build and when to stop? Constructing and repairing anatomies in novel circumstances is a remarkable example of the collective intelligence of a biological swarm. I propose that a multi-scale competency architecture is how evolution exploits physics to achieve robust machines that solve novel problems. I will describe what is known about developmental bioelectricity — a precursor to neurobiology which is used for cognitive binding in biological collectives, that scales their intelligence and the size of the goals they can pursue. I will also discuss the cognitive light cone model, and conclude with examples of synthetic living machines — a new biorobotics platform that uses some of these ideas to build novel primitive intelligences. I will end by speculating about ethics, engineering, and life in a future that integrates deeply across biological and synthetic agents.